POPULARITY
215 episodes with hsct
7 episodes with hsct
8 episodes with hsct
5 episodes with hsct
5 episodes with hsct
6 episodes with hsct
4 episodes with hsct
7 episodes with hsct
6 episodes with hsct
Welcome back to another episode of We Are Not MS!This week i have a guest who you will find very inspiring. Francesca's journey with her health, has been a long one, but her attitude and tenacity are really something else.Listen in especially if you are interested in hearing more about HSCT and what that process actually entails.I really hope you enjoy this weeks episode xx
Warrior: Anthony Ramirez AI: caregiver for son with MS HSCT: December 12, 2016 Superpower: resilience To what extent do you appreciate the journey? What version of yourself do you present to the world? After a concussion landed Anthony in the ER, his diagnosis of multiple sclerosis was not easy to understand, especially when the disease-modifying drugs did not work like other medications. As he dove into research to try to find more answers, he and his mom Cindi (see Episode 107) happened upon a brief mention of Dr. Burt's research at Northwestern University and committed to learn everything possible about the latest treatments. Tune in to hear more of Anthony's journey through HSCT and how he is faring now, nearly 9 years post-transplantand learn how her son is doing nearly nine years after undergoing HSCT. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore information about locations. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to audio guru Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician. Resources: Ataxia Center, Johns Hopkins
Warrior: Cindi Ramirez AI: caregiver for son with MS HSCT: December 12, 2016 Superpower: resilience How determined are you to find the best care? When her son suffered a concussion at a company picnic, a CT scan revealed a diagnosis of Multiple Sclerosis. Determined to get him the best care, Cindi sought out top-tier treatment at the Cleveland Clinic, but even with disease-modifying therapies, his symptoms continued to progress. After months of research, Cindi came across a webinar discussing stem cell research led by Dr. Burt at Northwestern University, and together they decided to pursue HSCT. Tune in to hear Cindi's heartfelt journey as both a mother and caregiver, and learn how her son is doing nearly nine years after undergoing HSCT. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore information about locations. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to audio guru Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician.
Warrior: Larry Powalisz AI: Primary Progressive Multiple Sclerosis HSCT: May 2022 Superpower: humbled by MS How dedicated are you to health and wellness? How committed are you to helping people halt autoimmune disease? After Larry's left hand went numb and he was diagnosed with MS, the only option his neurologist offered was Ocrevus. His research led him to HSCT at Clinica Ruiz. Upon returning home, Larry was inspired to help others gain access to HSCT and he founded a nonprofit organization to help cover the costs, but soon learned that fundraising for HSCT was not enough. He then founded Adia Med, now a publicly traded company to offer HSCT and other treatments to people battling autoimmune diseases. Tune in to learn more about Larry's journey with HSCT, how he is a guinea pig at Adia, and his dedication to making HSCT more accessible to individuals with autoimmune disease. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore information about locations. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to audio guru Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician. Resources: Adia Med outpatient HSCT clinic in Winter Park, Florida MS Heal the World nonprofit organization MS Hope and the Best Bet Diet for MS Brandon Bieber, neurologist Aaron Boster, neurologist Richard Burt, Everyday Miracles
Warrior: Ali Strong AI: Multiple Sclerosis HSCT: November 2017 Superpower: wellness When doctors aren't able to answer your questions, who do you turn to? Are you someone who strives to find answers? Do you find the present in each day? The beginning of a new season offers the opportunity to check in with Ali and how she is faring, more than seven years post-HSCT. Tune in to learn how HSCT has shifted her symptoms and experience with MS, gain updates on Ali's health and approach to wellness, and learn how she is focusing her energy these days. Be sure to visit HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, and connect with resources and the HSCT Warriors Inc nonprofit. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to create the soundtrack, and audio genius Jacob Kinch for sharing his superpowers to edit and produce the audio to make this podcast possible. Find us and subscribe to the HSCT Warriors Podcast on SoundCloud, iTunes, or wherever you find podcasts. It has been great to connect with Warriors worldwide and we would love to hear from you about how the podcast has helped your journey with autoimmune disease… take a moment to connect with us on instagram or share this episode with someone you know that would enjoy listening. In the meantime, we hope you'll tune in for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician immediately.
Can you recognize and treat transplantation-associated thrombotic microangiopathy (TA-TMA)? Join our experts for an in-depth discussion on diagnosis and management. Credit available for this activity expires: 01/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewhttps://www.medscape.org/viewarticle/advancing-care-hsct-tma-strategies-early-recognition-and-2025a10000p7?ecd=bdc_podcast_libsyn_mscpedu
Conversations in IFN-y explores the latest advancements in understanding and managing secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with updates from ASH 2024. Featuring discussions by leading experts, the educational activity covers breakthroughs in diagnostic technologies. Topics covered include AI-based histology models and PET/CT imaging, therapeutic innovations such as emapalumab and reduced-intensity conditioning for HSCT. The implications of these findings for improving outcomes in diverse patient populations, including malignancy- and pregnancy-associated HLH will also be discussed.Launch Date: January 9, 2025Release Date: January 9, 2025Expiration Date: December 31, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.
In episode ten of Getting to Know Your Research, Dr. Rebecca Levy discusses her 2021 William Weston Career Development Award to Characterize the Cutaneous Late Effects in Pediatric Hematopoietic Stem Cell Transplantation Recipients. In collaboration with the Hematopoietic Stem Cell Transplantation (HSTC) Late Effects Clinic at the Hospital for Sick Children in Toronto, Canada, this project aims to analyze data from linked provincial databases to define the risks and predictions of skin cancers in individuals who underwent HSCT. Listen to learn more about her findings and what this means for patients.
Jake Noble, PharmD, MPH reviews management of respiratory syncytial virus in patients undergoing allogeneic hematopoietic stem cell transplant. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE
In this World Shared Practice Forum Podcast, experts from three large pediatric hospitals discuss their collaborative care models designed to optimize care for patients undergoing hematopoietic stem cell transplant. This global panel reviews the history, structure, and current state of these models, and offers insight into how clinicians can develop and improve their own collaborative care models. LEARNING OBJECTIVES - Identify the importance of collaborative care models for hematopoietic stem cell transplant patients - Discuss the status of current care models in three pediatric stem cell transplant programs - Apply insights on how clinicians develop collaborative care models and steps that can be taken to make ongoing improvements AUTHORS Asya Agulnik, MD, MPH Associate Member, St. Jude Faculty Director, Global Critical Care Program Director, Euro Regional Program St. Jude Children's Research Hospital Indira Jayakumar, MD Lead Pediatric Intensivist Apollo Specialty Cancer Hospitals Co Convenor- IAP Transplant Critical Care, Chairman- Pediatric wing, ECMO Society of India Chennai, Tamil Nadu, India Leslie Lehmann, MD Attending Physician, Pediatric Stem Cell Transplant Center Boston Children's Hospital/Dana Farber Cancer Institute Associate Professor of Pediatrics Harvard Medical School Revathi Raj, MBBS, DCH, PLAB, MRCP, FRCPath Senior Consultant Department of Pediatric Hematology and Oncology and Blood and Marrow Transplantation Apollo Hospitals Chennai, Tamil Nadu, India Adrienne Randolph, MD, MSc Senior Associate in Critical Care Medicine, Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anaesthesia and Pediatrics Harvard Medical School Aimee C. Talleur, MD Assistant Member, Department of Bone Marrow Transplantation and Cellular Therapy Fellowship Director, BMTCT Fellowship Program St. Jude Children's Research Hospital DATES Initial publication: August 26, 2024. ARTICLES REFERENCED • Zinter MS, McArthur J, Duncan C, et al. Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network's Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup. Pediatr Crit Care Med. 2022;23(3):205-213. doi:10.1097/PCC.0000000000002865 (13:04) • St. Jude Global Critical Care program, https://global.stjude.org/en-us/programs/transversal-programs/critical-care.html, Email: globalcriticalcare@stjude.org (25:49) Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access-and thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Agulnik A, Jayakumar I, Lehmann L, Raj R, Randolph AG, Talleur AC, Wolbrink TA. Collaborative Care Models to Optimize Care of Hematopoietic Stem Cell Transplant Patients. 08/2024. OPENPediatrics. Podcast https://soundcloud.com/openpediatrics/collaborative-care-models-to-optimize-care-of-hsct-patients-by-t-wolbrink-et-al-openpediatrics.
In this week's episode we'll discuss how immune fitness impacts response to teclistamab in relapsed/refractory multiple myeloma; learn more about a new mechanism of resistance to asciminib conferred by the BCR::ABL1 M244V mutation, and discuss the impact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease. Featured Articles:Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminibImpact of hematopoietic cell transplantation on myocardial fibrosis in young patients with sickle cell disease
Here is another incredible Voice in the campaign - Sarah Doherty sharing her journey to being diagnosed with MS (Multiple Sclerosis) at the age of 27 after having several episodes of optic neuritis. MS is an autoimmune condition that attacks the brain/spinal cord/nervous system causing demyelination - a neurological condition which manifests differently for each person and affects women more than men. Sarah's story is a true example of the need for patient's to do their own research and know how to self-advocate the right way. MS has a wide range of treatment options which vary greatly depending on postcode, and when Sarah discovered she had 'patient choice' of where to be treated and to make informed decisions about her treatment, this massively influenced her journey. Sarah is currently about to start Stage 2 of the HSCT journey (stem cell transplant) which hopes to greatly reduce the chances of her having any more relapses, and has currently undergone 'conditioning chemotherapy' in preparation for this. Sarah is a wonderfully light hearted soul who is full of humour and emphasises the importance of staying positive through a difficult diagnosis.Mortal and Strong is a charity-run campaign using art to shine the spotlight on women facing their own mortality - those affected at a young age by a life changing illness or disease. 100 Voices sharing messages of hope and strength through our podcast with a powerful photography series ‘Scars of Gold' inspired by kintsugi. Building a platform to provide health awareness, support and education to change the face of disease in young people. Founded by Dr Liz Murray. For more information on support available for these issues discussed in todays episode, including direction to medical information, visit our website. This episode is not intended as specific medical advice, always see your own GP/physician if you have any concerns regarding your own health. #mortalandstrong #scarsofgold #kintsugi #art #artist #doctor #charity #campaign #womenshealth #cancer #nonhodgkinslymphoma #thyroidcancer #breastcancer #stemcelltransplant #lupus #autoimmunedisease #ms #hsct #conditioningchemotherapy #opticneuritis #disability #trauma #sepsis #podcast Hosted on Acast. See acast.com/privacy for more information.
In this week's episode we'll discuss the safety and efficacy of decitabine in older patients with AML; learn how heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice, and discuss the outcomes of treatment with HLA-mismatched HSCT with TCRab/CD19 lymphocyte depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Featured Articles:Decitabine in older patients with AML: Quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase III trial Heme induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice Outcomes of HLA-mismatched HSCT with TCRab/CD19 depletion or post-HSCT cyclophosphamide for inborn errors or immunity
Warrior: Veena Kinni AI: Multiple Sclerosis HSCT: Cleveland Clinic, 2021 Superpower: ability to know inner strength How fully do you embrace opportunities to enjoy life? How do you promote a positive mindset? As a trained physician, it was hard for Veena as she transitioned to being a patient after she was diagnosed with multiple sclerosis in December of 2011. She began on a disease-modifying therapy that she paused in order to get pregnant, though soon after delivering her daughter, her symptoms flared. Between 2014 and 2020, Veena's condition continued to deteriorate until 2020 when she visited a neurologist at the Cleveland Clinic who suggested HSCT and embraced the opportunity with an ‘ignorance is bliss' mindset. While she believes that it halted the progression of her disease, and shows no active lesions on MRI, the procedure and recovery have been challenging for Veena, which she attributes to being in the secondary progressive phase of disease. Tune in to learn more about Veena's experience, her transition to JC+ during treatment with disease modifying therapy, and why she agrees that pursuing HSCT sooner in the course of the experience with autoimmune disease to avoid lasting damage. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore information about locations. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician. Resources: Center for Regnerative Biotherapeutics Vinna Kinni, MD Multiple Sclerosis Defeater (blog)
To what extent are you able to eliminate stress from your life? Do you believe you can achieve whatever you put your mind to? To what extent are you aware of treatment options? Despite noticing some symptoms that interfered with walking and mobility, Janet postponed seeing doctors until after she retired from being a police officer. While Janet did not find her career to be stressful, she did experience intense stress in her relationships and personal life. Once Janet came down with bouts of hives caused by intense, long-sustained stress, she began taking steps to reduce and eliminate stress from her life. Over time, Janet experienced other stressors and symptoms (like foot drop and optic neuritis) that she was able to explain away at the time they occurred, but upon reflection, realized they were all related to her eventual diagnosis of multiple sclerosis in March of 2020. Tune in to learn more about how Janet explored options for HSCT in the US and Mexico, prepared her body physically for HSCT, developed strong feelings about accessibility to HSCT, found motivation to write a book about her experience and help others, and ended up having a complete reversal of symptoms. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore information about locations. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician.
In this episode of your third favourite, above average, but infinitely curious podcast DIMED OUT…I finally reach Day Zero and celebrate my Stem Cell Birthday, during which I experienced a mix of (positive) feelings and an unexpected hallucination.I also reflect on my time in Puebla, and my overall experience with HSCT. For More Information on HSCT and Clinica Ruiz - head to https://hsctmexico.com/ms_landing?gclid=CjwKCAjwp4m0BhBAEiwAsdc4aAa-C4RsLwb76c5lpHgW4W26k4B8plONPVoj4vtKbcmN1WDnz3bUfhoCmW8QAvD_BwE Follow Me on the Gram' https://www.instagram.com/iammalfoster/ Kofi (or Tea?) https://ko-fi.com/dimedout DIMED OUT is an anthropological Podcast dedicated to exploring the mysteries and meaning of life. An audio kaleidoscope of culture and society, alternative lifestyles and life experiences. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dimedout/message
In this episode of your third favourite, above average, but infinitely curious podcast DIMED OUT... I finally find myself at Clinica Ruiz in Puebla, Mexico to undergo my HSCT treatment. In this episode I discuss the initial surrealism of being there, along with my experiences of Chemotherapy, The Great Stem Cell Harvest of 2024 and my overall experience in the first two weeks. Next week I'll be covering the actual Stem Cell transplant, the neutropenic period after, and my overall experience of HSCT. For More Information on HSCT and Clinica Ruiz - head to https://hsctmexico.com/ms_landing?gclid=CjwKCAjwp4m0BhBAEiwAsdc4aAa-C4RsLwb76c5lpHgW4W26k4B8plONPVoj4vtKbcmN1WDnz3bUfhoCmW8QAvD_BwE Follow Me on the Gram' https://www.instagram.com/iammalfoster/ Kofi (or Tea?) https://ko-fi.com/dimedout DIMED OUT is an anthropological Podcast dedicated to exploring the mysteries and meaning of life. An audio kaleidoscope of culture and society, alternative lifestyles and life experiences. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dimedout/message --- Send in a voice message: https://podcasters.spotify.com/pod/show/dimedout/message
In this episode of your third favourite, above average, but infinitely curious podcast DIMED OUT... The months, weeks, and days are counting down until I head to Puebla, Mexico for HSCT treatment. In this second of a two parter, I go through my mental/emotional state and the practical preparation ahead of my Stem Cell Transplant. Follow Me on the Gram' https://www.instagram.com/iammalfoster/ Kofi (or Tea?) https://ko-fi.com/dimedout DIMED OUT is an anthropological Podcast dedicated to exploring the mysteries and meaning of life. An audio kaleidoscope of culture and society, alternative lifestyles and life experiences. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dimedout/message --- Send in a voice message: https://podcasters.spotify.com/pod/show/dimedout/message
At the 2024 European Hematology Association (EHA) Congress, CancerNetwork® spoke with a variety of experts in the hematologic oncology space about optimizing outcomes across different patient populations and subgroups based on updated research they presented at the meeting. Manali Kamdar, MD, an associate professor of medicine-hematology and clinical director of Lymphoma Services at the University of Colorado Anschutz Medical Campus, in Colorado, spoke about data from the phase 1 TRANSCEND NHL 001 trial (NCT02631044) supporting the use of lisocabtagene maraleucel (liso-cel; Breyanzi) in earlier lines of therapy for patients with relapsed/refractory mantle cell lymphoma (MCL).1 Specifically, Kamdar highlighted how research should continue to focus on the potential utility of liso-cel in MCL subgroups such as those with TP53 mutations or blastoid morphology. Additionally, she stated that liso-cel may need to be further tested in earlier lines of therapy for patients with diffuse large B-cell lymphoma, including those with double-hit lymphoma. Michael R. Grunwald, MD, chief of the Leukemia Division and director of the Transplantation and Cellular Therapy Program at Atrium Health's Levine Cancer Institute, in North Carolina, discussed findings from the Prospective Observational Study of Patients With Polycythemia Vera (PV) in US Clinical Practices Trial (REVEAL) exploring risk factors for disease progression in patients with polycythemia vera (PV).2 According to Grunwald, a history of thromboembolic events, elevated white blood cell counts, and higher variant allele frequencies may contribute to a patient's likelihood of experiencing progression to myelofibrosis or acute myeloid leukemia (AML). Additionally, he highlighted ongoing research into the potential molecular factors that may prognosticate disease transformation in PV among a small cohort of patients enrolled on the REVEAL trial.3 Harry P. Erba, MD, PhD, a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy and the director of the Leukemia Program and Phase I Development in Hematologic Malignancies at Duke Cancer Institute, in North Carolina, discussed the clinical implications of data from the phase 3 QuANTUM-First study (NCT02668653).4 Specifically, findings demonstrated that continuation therapy with quizartinib (Vanflyta) elicited a more pronounced survival benefit vs placebo in patients with newly diagnosed FLT3-ITD–positive AML who did not undergo allogeneic hematopoietic stem cell transplant (allo-HSCT). However, Erba noted that survival outcomes were not significantly different in the quizartinib and placebo arms among patients who received allo-HSCT. References 1. Palomba ML, Siddiqi T, Gordon LI, et al. Subgroup analyses in patients with R/R MCL treated with lisocabtagene maraleucel by prior lines of therapy and response to Bruton tyrosine kinase inhibitor from the TRANSCEND NHL 001 MCL cohort. Presented at the European Hematology Association (EHA) 2024 Congress; Madrid, Spain; June 13-16, 2024. P1126. 2. Grunwald M, Zwicker J, Gerds A, et al. A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV) enrolled in REVEAL. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract P1047. 3. Crowgey E, Timmers C, Xue Z, et al. Analysis of molecular mechanisms and predictive biomarkers of disease transformation in polycythemia vera. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S217. 4. Sekeres MA, Erba H, Montesinos P, et al. QuANTUM-First: efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation therapy. Presented at the 2024 European Hematology Association (EHA) Congress; June 13-16, 2024; Madrid, Spain. Abstract S142.
In this podcast episode, Dr. Jonathan H. Westover talks with Jesan Sorrells about the role of leadership development in a world of artificial intelligence. Jesan Sorrells (https://www.linkedin.com/in/jesansorrells/) is the CEO and Founder of HSCT Publishing, LLC. HSCT is remote-first, video-based, software publishing platform company located in the Dallas-Fort Worth Metroplex. HSCT seeks to help organizations manage and reduce the impact of workplace conflict, encourage organizational innovation, and increase optimal outcomes around leadership development, conflict management, and change management. HSCT leverages content platforms, training, and education via their Leadership Toolbox and LeadingKeys products. Jesan's latest book 12 Rules for Leaders: The Foundation of Intentional Leadership (2022) advances the idea that all problems in all organizations can be solved through the intentional application of effective leadership practices and principles. Leaders who have heard Jesan's message have changed cultures changed organizations and changed their work lives by changing their mindsets, their teams, and their organizations. Jesan hosts and produces the Leadership Lessons from the Great Books podcast, and previously published Marketing for Peace Builders: How to Market Your Value to a World in Conflict, in 2016 and My Boss Doesn't Care: 100 Essays on Disrupting Your Workplace by Disrupting Your Boss, in April 2019. Check out all of the podcasts in the HCI Podcast Network! Check out the HCI Academy: Courses, Micro-Credentials, and Certificates to Upskill and Reskill for the Future of Work! Check out the LinkedIn Alchemizing Human Capital Newsletter. Check out Dr. Westover's book, The Future Leader. Check out Dr. Westover's book, 'Bluer than Indigo' Leadership. Check out Dr. Westover's book, The Alchemy of Truly Remarkable Leadership. Check out the latest issue of the Human Capital Leadership magazine. Each HCI Podcast episode (Program, ID No. 655967) has been approved for 0.50 HR (General) recertification credit hours toward aPHR™, aPHRi™, PHR®, PHRca®, SPHR®, GPHR®, PHRi™ and SPHRi™ recertification through HR Certification Institute® (HRCI®). Each HCI Podcast episode (Program ID: 24-DP529) has been approved for 0.50 HR (General) SHRM Professional Development Credits (PDCs) for SHRM-CP and SHRM-SCPHR recertification through SHRM, as part of the knowledge and competency programs related to the SHRM Body of Applied Skills and Knowledge™ (the SHRM BASK™). Human Capital Innovations has been pre-approved by the ATD Certification Institute to offer educational programs that can be used towards initial eligibility and recertification of the Certified Professional in Talent Development (CPTD) and Associate Professional in Talent Development (APTD) credentials. Each HCI Podcast episode qualifies for a maximum of 0.50 points.
In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell transplantation with post-transplant cyclophosphamide.Featured Articles: Wiskott-Aldrich Syndrome: A retrospective study on 577 patients defines the genotype as a predictive biomarker for disease severity and survivalLoss of Dnmt3a increased self-renewal and resistance to pegylated interferon-alpha in JAK2-V617F-positive myeloproliferative neoplasms Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
In this episode of your third favourite above average but infinitely curious podcast DIMED OUT... Following my diagnosis of Multiple Sclerosis I have decided to undergo HSCT (Hematopoietic stem cell transplantation). I'll be receiving treatment at Clinica Ruiz in Puebla, Mexico. In the first of two parts, I'm detailing what HSCT is and why I've decided to go for it. For professional info on HSCT and Clinica Ruiz, I suggest you head here. https://hsctmexico.com/ Follow Me on the Gram' https://www.instagram.com/iammalfoster/ Kofi (or Tea?) https://ko-fi.com/dimedout DIMED OUT Dimed Out is an anthropological Podcast dedicated to exploring the mysteries and meaning of life. An audio kaleidoscope of culture and society, alternative lifestyles and life experiences. --- Send in a voice message: https://podcasters.spotify.com/pod/show/dimedout/message
Acute myeloid leukemia (AML) is a cancer characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. ABT199, also known as venetoclax, is a targeted therapy that inhibits the BCL-2 protein, which is often overexpressed in AML cells and contributes to their survival. By blocking this protein, venetoclax can trigger apoptosis, or programmed cell death, in cancer cells. Thiotepa, a DNA alkylating agent, has been used in conditioning regimens for hematopoietic stem cell transplantation (HSCT) but its combination with ABT199/venetoclax has not been thoroughly explored, until now. In a new study, researchers Benigno C. Valdez, Bin Yuan, David Murray, Jeremy L. Ramdial, Uday Popat, Yago Nieto, and Borje S. Andersson from The University of Texas MD Anderson Cancer Center and the University of Alberta investigated a promising new approach to AML therapy by combining multiple drugs to enhance cytotoxic effects on AML cells. On March 14, 2024, their new research paper was published in Oncotarget's Volume 15, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.” Full blog - https://www.oncotarget.org/2024/04/11/synergistic-effects-of-drug-combinations-targeting-aml-cells/ Paper DOI - https://doi.org/10.18632/oncotarget.28563 Correspondence to - Benigno C. Valdez - mbalasik@yahoo.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28563 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, acute myeloid leukemia, aml, pre-transplant regimens, venetoclax, thiotepa, busulfan About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
BUFFALO, NY- March 25, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 14, 2024, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.” ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment. Its efficacy in hematopoietic stem cell transplantation (HSCT), when combined with other chemotherapeutic drugs, has not been thoroughly investigated. In this new study, researchers Benigno C. Valdez, Bin Yuan, David Murray, Jeremy L. Ramdial, Uday Popat, Yago Nieto, and Borje S. Andersson from The University of Texas MD Anderson Cancer Center and the University of Alberta demonstrate the synergistic cytotoxicity of ABT199/venetoclax with the DNA alkylator thiotepa (Thio) in AML cells. “The results may provide relevant information for the design of clinical trials using these drugs to circumvent recognized drug-resistance mechanisms when used as part of pre-transplant conditioning regimens for AML patients undergoing allogenic HSCT.” Cleavage of Caspase 3, PARP1 and HSP90, as well as increased Annexin V positivity, suggest potent activation of apoptosis by this two-drug combination; increased levels of γ-H2AX, P-CHK1 (S317), P-CHK2 (S19) and P-SMC1 (S957) indicate an enhanced DNA damage response. Likewise, the increased level of P-SAPK/JNK (T183/Y185) and decreased P-PI3Kp85 (Y458) suggest enhanced activation of stress signaling pathways. These molecular readouts were synergistically enhanced when ABT199/venetoclax and Thio were combined with fludarabine, cladribine and busulfan. The five-drug combination decreased the levels of BCL-2, BCL-xL and MCL-1, suggesting its potential clinical relevance in overcoming ABT199/venetoclax resistance. Moreover, this combination is active against P53-negative and FLT3-ITD-positive cell lines. Enhanced activation of apoptosis was observed in leukemia patient-derived cell samples exposed to the five-drug combination, suggesting a clinical relevance. “The results provide a rationale for clinical trials using these two- and five-drug combinations as part of a conditioning regimen for AML patients undergoing HSCT.” DOI - https://doi.org/10.18632/oncotarget.28563 Correspondence to - Benigno C. Valdez - mbalasik@yahoo.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28563 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, acute myeloid leukemia, aml, pre-transplant regimens, venetoclax, thiotepa, busulfan About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Warrior: Christian AI: Multiple Sclerosis HSCT: 11/3/23 at the Tom Baker Cancer Center in Calgary Superpower: body awareness What is your capacity for listening to your body? How well do you fare through complications? How comfortable are you with looking inward? After the numbness and tingling in his legs restricted his capacity to walk in the course of just a few weeks, Christian was quickly diagnosed after finding the right doctor who knew what his symptoms were indicating. After cycling through a variety of disease-modifying therapies over the course of seven years, Christian continued relapsing. After the humbling and terrifying experience of being wheelchair-bound for a few months in December of 2022, Christian switched DMTs again and after it didn't stop new lesions, he was eventually referred for HSCT in Calgary in June of 2023. Tune in to learn more about the circumstances that led Christian to pursue HSCT in Calgary, and how he fared through the myeloablative protocol, including complications and resolutions. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore information about locations. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician.
Welcome to Living Well with MS, where we are pleased to welcome Dr Stefano Pluchino as our guest! Dr Pluchino is a Professor of Regenerative Neuroimmunology at Cambridge University and has been researching stem cell therapy for progressive MS. In this episode, Dr Pluchino speaks to Geoff about what advanced cell therapy is, the success of his phase one trial and what the future of DMTs looks like indicating what people with MS may experience. Watch this episode on YouTube here. Keep reading for the key episode takeaways. Topics and Timestamps: 01:31 Dr Pluchino's background and research into stem cell therapy for progressive MS. 02:52 The difference between types of MS. 05:09 Navigating DMT options for progressive MS. 08:40 Dr Pluchino's advanced cell therapy research trial: The success of phase one and plans for phase two. 21:05 How advanced cell therapy compares to HSCT or bone marrow transplants. 26:02 What it means for the future of DMTs. 33:39 How you can be part of groundbreaking MS research and trials. Selected Key Takeaways: There are nuances in types of MS beyond ‘relapsing' or ‘progressive'. 04:23 "It is becoming more complex between active and non-active types of primary and secondary progressive MS where activity is attributed to other episodes. Clinical episodes of disease or radiologically evident episodes of disease, which can be identified by the use of contrast agents at the time of the MRI. So, they are very complex very heterogenous types of disease, with or without activity, which inevitably undergo accumulation of neurological deficits.” The next generation of DMTs will target progression rather than relapses. 06:39 “What's becoming very interesting is that [over the last] few years, there is a general worldwide consensus that progressive MS is becoming and has become a clinical unmet need. The old MS world is concentrating on financing, funding and efforts towards stopping MS through the development of a new generation of DMDs which will eventually target progression rather than relapses.” The future of advanced cell therapy research will look at remyelination, reduction of inflammation and neuroprotection. 19:10 "There is space for assessing whether a proportion of the injected cells [can] differentiate in vivo into new myelin-forming cells. There is a space to assess whether some of the cells [can] increase the survival of neurons in the brain. There is space to assess whether the transplanted cells [can] reduce the type of inflammation which characterises progressive MS, which is what we call a smouldering inflammation. These highly diffuse homogeneous, low-level activations of microglia (immune cells of the central nervous system) and astrocytes (star-shaped cells that hold nerve cells in place) might be reduced by means of advanced cell therapy and the reason why I am specifically alluding to these three major biological mechanisms of disease, remyelination, reduction of inflammation and neuroprotection is because we have managed to identify each of these mechanisms in clinically relevant animal disease models in the last 25 years. So, there is [an] expectation that a clinical trial designed in a way that will allow us to establish the efficacy of the treatment will reveal what we have established already in one of these models.” Want to learn more about living a full and happy life with multiple sclerosis? Sign up to our newsletter to hear our latest tips. More info and links: Video on Early-stage stem cell therapy trial shows promise for treating progressive MS Dr Pluchino's website Dr Pluchino's bio If you have progressive MS you may be eligible for the Octopus trial Learn about HSCT from Professor Richard Burt in Season 5 Episode 25 Read about the Shinya Yamanaka and John Gurdon'a Nobel Winning iPSC technology Find out more about the latest research in progressive MS from the International Progressive MS Alliance New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS.
Dr. Lisa Law and Dr. Randy Taplitz share the latest evidence-based recommendations from ASCO on vaccines in adults with cancer. They discuss recommended routine preventative vaccinations, additional vaccinations and revaccinations for adults undergoing HSCT, CD19 CAR-T treatment, or B cell-depleting therapy, guidance for adults with cancer traveling outside the U.S., and recommendations for vaccination of household and close contacts of adults with cancer. Dr. Law and Dr. Taplitz also share their insights on the guideline, including the importance of this guideline for adults with cancer and their clinicians, future advances in research, and current unmet needs. Read the full guideline, “Vaccination of Adults with Cancer: ASCO Guideline” at www.asco.org/supportive-care-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.24.00032 The ASCO Specialty Societies Advancing Adult Immunization (SSAAI) Project is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award to the Council of Medical Specialty Societies (CMSS) (with 100 percent funded by CDC/HHS). The contents are those of the authors and do not necessarily represent the official views of nor endorsement, by CDC/HHS or the U.S. Government. Brittany Harvey: Hello, and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today, I am interviewing Dr. Lisa Law from Kaiser Permanente and Dr. Randy Taplitz from City of Hope Comprehensive Cancer Center, authors on “Vaccination of Adults with Cancer: ASCO Guideline.” Thank you for being here, Dr. Law and Dr. Taplitz. Dr. Lisa Law: Thank you. Dr. Taplitz: Thank you, Brittany. Brittany Harvey: Before we discuss this guideline, I'd like to take note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Taplitz and Dr. Law, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content, here first, Dr. Taplitz, can you provide a general overview of both the scope and purpose of this guideline on vaccination of adults with cancer? Dr. Randy Taplitz: Yes, so people with cancer often experience a compromised immune system due to a variety of factors. This includes chronic inflammation, impaired or decreased function of the hematopoietic system, and treatments that compromise their immune function. Because of this, people with cancer are at a higher risk for infection, including with vaccine-preventable diseases. Also, response to vaccines in patients with cancer may well be affected by this underlying immune status, and their anticancer therapy, as well as the severity of the underlying malignancy. The purpose of vaccination in this group of patients is to prevent infection or to attenuate the severity of the disease when infection cannot be fully prevented. This ASCO review builds on a 2013 guideline by the Infectious Diseases Society of America, or IDSA, and uses what's called a systematic literature review of 102 publications between 2013 and 2023. This includes 24 systematic reviews, 14 randomized clinical trials, and 64 non-randomized studies. The largest body of evidence in these studies, not surprisingly, addresses COVID vaccines on the efficacy and safety of vaccines used by adults with cancer or their household contacts. ASCO convened an expert panel to review this evidence and formulate recommendations for vaccinations in this population. Brittany Harvey: Understood. I appreciate that context, Dr. Taplitz. So then, next, Dr. Law, I'd like to review the key recommendations of this guideline. The guideline addresses four overarching clinical questions. So starting with the first question, what are the recommended routine preventative vaccinations for adults with cancer? Dr. Lisa Law: Thank you, Brittany. Before I start, I just want to wholeheartedly thank the first author of this paper, Dr. Mini Kamboj, Dr. Elise Kohn from the NCI, as well as the ASCO staff in putting this publication and guideline together. It is a very, very important guideline, and I echo everything Dr. Taplitz just said. So going back to your question, what are the recommended routine preventative vaccines for adults with cancer? As per this guideline, there are about 7 to 8 based on patient age and risk. Namely, they are: seasonal flu, RSV for those aged 60 or above, COVID-19, Tdap, Hepatitis B, Shingrix, Pneumococcal vaccine, and the HPV vaccine. These vaccines should ideally be given two to four weeks before therapy. However, non-live vaccines can be given anytime during or after chemo, immunotherapy, hormonal treatment, radiation, or surgery. Brittany Harvey: Excellent. Thank you for reviewing those vaccinations and the timing of them as well. So then, following those recommendations, Dr. Taplitz, what additional vaccinations and revaccinations are recommended for adults undergoing hematopoietic stem cell transplantation, CD19 CAR-T treatment, or B-cell depleting therapy? Dr. Randy Taplitz: Many studies have shown that stem cell transplant recipients essentially lose immunity from childhood immunizations, and we know that these individuals are very vulnerable to infection, particularly in the first year after transplant. Revaccination is critical to help restore their immunity. The optimal timing of vaccination is based on our understanding of adequate immune reconstitution with B and T-cell recovery so that the individual can mount a response to the vaccine. We know that a lot of factors influence this immune reconstitution, including the age of the stem cell transplant recipient, the source of the donor, the time from transplant, graft-versus-host disease prophylaxis, the treatment and severity of graft-versus-host disease, and the vaccine type and antigens used. There are a number of bodies throughout the world, IDSA as I mentioned, CDC, American Society for Transplant and Cellular Therapy, European Society for Blood and Marrow Transplant, and European Conference for Infections and Leukemia. All of these bodies have guidelines that approach vaccination in stem cell transplants. However, variation does exist in the use of a variety of things including whether to use immune predictors to help guide vaccination, and there is really not consensus on whether this immune predictor guided vaccination is more likely to produce a protective immune response versus a standardized schedule. In addition, the duration of protection is incompletely understood. The bottom line in these guidelines is that they recommend complete revaccination starting for most vaccines at 6 to 12 months after stem cell transplant, in order to restore vaccine-induced immunity. And I just want to go through a few of the particulars. For COVID-19, which is a three-dose series in the primary series, influenza - generally high-dose influenza - and pneumococcal vaccine, PCV20 in general, ultimately four doses, can be administered, starting as early as three months after transplant. Although there is really not much data to guide the use of the recombinant zoster vaccine in allogeneic stem cell transplant, the vaccine can be administered after the end of antiviral prophylaxis, which in general is 12 to 18 months after allogeneic and 3 to 12 months after autologous stem cell transplant. Some of the other vaccines, such as hepatitis B, Tdap, meningococcal vaccines, and HPV revaccination in those less than 45 are also recommended. I want to also spend the moment talking about the two recently licensed RSV vaccines, which were essentially studied in less compromised hosts and really without any immunogenicity data in stem cell transplant, and thus, there is no recommendation in this guideline for the use of these vaccines after transplant. Live vaccines, such as MMR and varicella – varicella would be in varicella-seronegative patients without a prior history of varicella – should be delayed for at least two years and only given in the absence of active graft-versus-host disease or immunosuppression. Moving briefly to CAR T, which is an immunotherapy that involves adoptive cell therapy, given the available data and after a review by the group, it was recommended that adults with hematopoietic malignancies receiving CAR T therapy directed against B-cell antigens should receive influenza and COVID-19 vaccines either two weeks before lymphodepletion or no sooner than three months after the completion of therapy. Administration of non-live vaccines preferably should occur before CAR T treatment or at least 6 to 12 months after, following the same timing as what we recommend for stem cell transplant. There is really little data to guide the safety and timing of administration of live vaccines after CAR T therapy. In terms of adults receiving B-cell depleting therapy, they are generally unable for time to mount an effective humoral response but may have at least partially intact cellular immune responses. They are encouraged to be revaccinated for COVID-19 no sooner than six months after completion of B-cell depleting therapy, and they should receive influenza vaccine approximately four weeks from the most recent treatment dose for patients on chronic therapy. For other non-seasonal immunizations, vaccines ideally should be given two to four weeks before commencing anti-CD20 therapy or delayed until 6 to 12 months after completion, except for the recombinant zoster vaccine, which can be given one month after the most recent dose of B-cell depleting therapy. Brittany Harvey: I appreciate you reviewing each of those vaccinations and when they should be given, and reviewing the available data – albeit, limited data – in these situations. So beyond these routine preventative vaccinations and revaccinations that you've both just described, Dr. Law, what additional vaccinations does the expert panel recommend for adults with cancer traveling outside the United States? Dr. Lisa Law: Good question. As per these ASCO guidelines, adults with solid or blood cancer traveling outside of the United States should follow the CDC standard recommendations for their destination. For the 2024 CDC Yellow Book, travel vaccines, in general, should be delayed until three months from the last chemotherapy or, and for those with solid tumors, ideally when the disease is in remission. Of note, hepatitis A, typhoid, inactivated polio, Hep B, rabies, meningococcal vaccine, and Japanese encephalitis vaccines are considered to be safe. In all cases of travel, patients should be counseled by their healthcare provider about the travel timing, with the additional attention to the regional seasonality of infections, for instance, influenza is more common in late summer in Australia, and also with attention to any outbreaks that may be occurring globally at the time of travel. Brittany Harvey: Absolutely. Those are key points for clinicians to discuss with their patients as they consider upcoming travel. So then, the final clinical question that the panel addressed, Dr. Taplitz, what vaccinations does the panel recommend for household and close contacts of adults with cancer? Dr. Randy Taplitz: Thank you. Yes, it is recommended that all household members and close contacts, when possible, be up to date on their vaccinations. And the only further thing I would say is that there are some special considerations for the use of live vaccines in household contacts, particularly in stem cell transplant recipients. Contacts of people who receive stem cell transplants should preferably receive inactivated influenza vaccines. As was mentioned, MMR and varicella vaccines are both safe to administer to close contacts. Vaccine strain transmission to immunocompromised hosts has not been associated with MMR use in family members. Eleven cases of the varicella vaccine strain transmission are described in the published literature, but none occurred in compromised hosts. Because the vaccine strain can cause severe and fatal varicella in profoundly immunocompromised people, precautions are advised to avoid close contact with a person with a vaccine-induced rash. For household contact travelers, MMR and yellow fever vaccines are considered safe. Oral cholera should be avoided. For smallpox vaccines, the second-generation ACAM2000 has rarely been associated with vaccinia transmission and should be avoided because of this. But the live replication-deficient MVA-based JYNNEOS vaccine is felt to be safe for household contacts of immunocompromised individuals. Brittany Harvey: I appreciate you reviewing the importance of vaccination for household and close contacts, and some of those precautions that individuals should take. I appreciate you both for reviewing all of these recommendations. So then in your view, Dr. Law, what is the importance of this guideline, and how will it impact both clinicians and adults with cancer? Dr. Lisa Law: In my opinion, this is a very important guideline that is long overdue in the oncology community and will have a huge impact on both clinicians and adults with cancer. Over the years, I have often been asked by my colleagues and patients, “Can I have the flu vaccine, and if so, when?” So this guideline really is going to be helpful. More importantly, our cancer patients are living much longer. They may have years of quality of life even with third or fourth line of treatment, especially, for instance, like CAR T for myeloma and lymphoma. However, we know that with additional treatment, that carries a substantial risk of infection complication among these immunocompromised patients. So it is of paramount importance to inform our patients and colleagues to be proactive in advocating preventive therapy ahead of time, meaning trying to get the patients appropriately vaccinated as early as possible to generate immunity. Another case in point is the Shingrix vaccine. I used to see lots of shingles, but ever since we have the recombinant Shingrix, I have fewer encounters. And this is huge because post-herpetic neuralgia robs a patient's quality of life. So, again, it is very important to recommend appropriate vaccines for our cancer patients. Brittany Harvey: Absolutely. It is key to ensure patients receive these preventative vaccines, and we hope that this guideline puts an emphasis on that for clinicians and patients. So finally, to wrap us up, Dr. Taplitz, what are the current gaps in knowledge regarding the vaccination of people with cancer? Dr. Randy Taplitz: There are a number of really important gaps in knowledge and really critical unmet needs that require research and other dedicated efforts. Among these are, and I think paramount, are really the participation of people with cancer with varied types of immunocompromise in vaccine trials. Where vaccine trials are only for cancer patients, obviously is ideal, testing vaccines in the appropriate population. But when that's not feasible, pre-existing cancer should not preclude eligibility, and inclusion of cohorts of people receiving anticancer treatment should be incorporated prospectively. So that's really critical because the quality of our guidelines is based upon the data. We use the data for developing guidelines and gathering more data in the particular patient population is really, really critical. Secondly, work for creating more immunogenic vaccines and research to understand the immune response to vaccines after immuno-depleting therapies, particularly with newer therapies such as CAR T and newer B cell therapies, bispecific antibodies, etc. is really critical. We need to really understand the immune response and have the most potent vaccines available to these people who may have impaired immune responses. Switching gears a little bit, we really need mechanisms to promote institutional commitment to integrate and sustain immunization best practices for people with cancer. This will largely be through multidisciplinary, team-based approaches, protocol-based vaccination standing orders, and leveraging data sharing so that we can all be on the same page with giving vaccines to these individuals. We also need education and evidence-based decision-making tools, emphasizing preventive care through immunization, the availability of educational resources to clinicians and patients to address commonly asked questions and also misconceptions about vaccination, that's absolutely critical. And finally, I think we need to develop strategies for addressing unique challenges and factors contributing to vaccine hesitancy during cancer therapy. We need to focus on patient and clinician communication, and very importantly, we need to consider health equity considerations in the development and approach to vaccines in these compromised patients. Brittany Harvey: Definitely, we'll look forward to research and advances in these areas that you've just described to support these guidelines and increase vaccine uptake. So I want to thank you both so much for your work on this important guideline, and thank you for your time today, Dr. Law and Dr. Taplitz. Dr. Lisa Law: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Warrior: Fiona Mitten AI: Marburg's variant of Multiple Sclerosis HSCT: 12/29/2011 Superpower: living in the moment Are you someone who believes that everything happens for a reason? How many moments do you treasure each day? Diagnosed 18 years ago after being hit by a drunk driver, several symptoms of multiple sclerosis like optic neuritis and paralysis onset and progressed so quickly, it seems Fiona's experience was extra unique from the start. From bouts of total paralysis that kept her hospitalized for months at a time, to relief from rounds of chemotherapy that had her walking again, to severe withdrawal that led to chemo-induced psychosis, by the time Fiona found her way to HSCT, she was struggling to walk (a requirement to pass the testing in order to qualify for HSCT). Tune in to learn how Fiona became the third person to be transplanted outside of the trials in Calgary, how she fared with HSCT and recovery, and how she is doing twelve-plus years post-HSCT. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore information about locations. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician.
Warrior: Ali Strong AI: Multiple Sclerosis HSCT: November 2017 Superpower: boundaries Are you someone who feels your emotions? Are you one to choose happiness? Do you find the present in every moment? The beginning of a new season offers the opportunity to check in with Ali and how she is faring, more than six years post-HSCT. Tune in to revisit the struggles with active multiple sclerosis, hear how HSCT has shifted her symptoms and experience with MS, and learn how Ali is focusing her energy these days. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore the world map. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and to Jacob Kinch for engineering the audio to make this podcast possible. You can find us when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician.
This is Ep. 1 of SHEA's three-part series, Developments in Transmission-based Precautions. This episode focuses on preventing respiratory virus infections in patients with neutropenia or those undergoing hematopoietic stem cell transplantation. We'll explore characteristics of the patient population or local epidemiological trends that might warrant additional precautions and our speakers will provide a synopsis of the recommendations or data used to substantiate such measures. Speakers: Mini Kamboj, MD Lynne Strasfeld, MD Moderator: Chad Nix, MSc, CIC
A couple of terms have found their way into the MS lexicon and they have left some people living with MS feeling confused and even frightened. If you've been diagnosed with relapsing-remitting MS and you've always assumed that disease progression only occurs at the time of a relapse, you may be wondering what progression independent of relapse activity, or PIRA, means and how it may or may not impact your MS journey. And if you are someone whose MS seems relatively stable and well-managed, you may be wondering whether your central nervous system is under some sort of silent attack from smoldering MS. Professor Alan Thompson joins me this week to shine a bright light on what, for many, are anxiety-inducing terms and help us understand what they are actually attempting to describe. Professor Thompson is the recipient of virtually every high honor and award that's given in the field of multiple sclerosis research, including the John Dystel Prize for MS Research in 2017, the Sobek Research Prize in 2020, and the 2021 Charcot Award, which recognizes a lifetime of achievement in outstanding research into understanding and treating MS. We're also sharing results of a study that suggests that kids and teens who are living with MS may experience better outcomes if they are started on a high-efficacy disease-modifying therapy. We'll tell you about a study that adds to the evidence that autologous hematopoietic stem cell transplantation may be a highly effective treatment that allows some people living with MS to live symptom-free and even return to the workforce. We're sharing the details of an AI tool that can predict an individual's disease course, while we're talking about survey results that show some strong push-back from the patient community when it comes to using artificial intelligence in the diagnostic process. And we'll tell you about a study that shows that caffeine may improve balance, mobility, and even quality of life for people living with MS. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: What is "Progression Independent of Relapse Activity"? 1:31 STUDY: High-efficacy disease-modifying therapies are shown to be effective in treating pediatric onset MS 3:02 STUDY: Compelling evidence for autologous hematopoietic stem cell transplantation (HSCT) as an effective treatment for MS 6:49 An AI tool has been developed that can predict an individual's MS disease course 9:17 SURVEY: Some people have mixed feelings about using AI in diagnosing illness 11:47 STUDY: Caffeine is shown to improve balance and mobility in people with MS 14:38 Professor Alan Thompson helps define a couple of terms that people with MS may find confusing and even worrisome 16:47 Share this episode 28:15 Have you downloaded the free RealTalk MS app? 28:35 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/339 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com STUDY: Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis https://jamanetwork.com/journals/jamaneurology/fullarticle/2814784 STUDY: Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Long-Term Follow-Up Data from Norway https://journals.sagepub.com/doi/10.1177/13524585241231665 STUDY: Predicting Disease Severity in Multiple Sclerosis Using Multimodal Data and Machine Learning https://link.springer.com/article/10.1007/s00415-023-12132-z SURVEY: Consumer Perceptions of Second Opinions and Concierge Health Services https://clinicbyclevelandclinic.com/consumer-perceptions-report STUDY: Potential Efficacy of Caffeine Ingestion on Balance and Mobility in Patients with Multiple Sclerosis: Preliminary Evidence from a Single-Arm Pilot Clinical Trial https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297235 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 339 Guest: Professor Alan Thompson Privacy Policy
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!
Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176) Hosted on Acast. See acast.com/privacy for more information.
In this week's episode, we'll learn how the diversity of gut microbiota predicts mortality and acute graft-versus-host disease in pediatric allogeneic transplant recipients. Then we'll discuss complement inhibition in patients with complement-mediated atypical hemolytic uremic syndrome. Finally we'll learn how PD-1 plus HDAC equals responses in previously treated Hodgkin lymphoma, specifically that response rates were encouraging in a heavily pretreated cohort, even among patients with PD-1 refractory disease.
Dr. Paul Orchard is the Medical Director of the Inherited Metabolic and Storage Disease Program and a Professor in the Department of Pediatrics in the Division of Blood and Marrow Transplant & Cellular Therapy (BMT & CT) at the University of Minnesota. He is interested in using hematopoietic stem cell transplantation (HSCT) and other cell therapies, including gene therapy, to improve outcomes. In addition to his clinical work with patients with inherited metabolic diseases, Dr. Orchard is engaged in research designed to identify strategies that enhance the delivery of enzymes to the brain and the peripheral nervous system for patients who lack specific enzymes. Other interests include the modification of stem cell transplant approaches and combination therapies to improve outcomes for patients with inherited diseases and the potential to develop multi-institutional cooperative studies for these disorders. Listen to a leading expert in saving the lives of children every day, including Dr. Amy Brower's son.
Welcome to Living Well with MS, where we are pleased to welcome Professor Richard Burt as our guest! Professor Burt is a leading expert in hematopoietic stem cell transplantation (HSCT) for autoimmune diseases including MS and has been awarded a number of prestigious accolades. Watch this episode on YouTube here. Keep reading for the key episode takeaways and Professor Burt's bio. Questions and Timestamps 02:35 Could you introduce yourself and tell us about your work with patients with autoimmune conditions and MS? 12:03 What do you think about the idea of flipping the model and offering the most aggressive treatment options to patients first? 16:27 What are the risks of HSCT? 21:18 Can you tell us about the costs associated with stem cell transplantation? 24:13 What type of patients respond best to HSCT? 31:16 Do you see a future where doctors are trained in multiple fields and understand the whole picture of autoimmunity? 38:10 If someone's interested in exploring HSCT, what should they look for in a clinic or physician? 41:47 HSCT has a high upfront cost but how does that compare to being on an MS drug for years or perhaps a lifetime? 53:50 The Dalai Lama wrote the introduction to your book 'Everyday Miracles'. How did that come about? Selected Key Takeaways Randomised controlled trial results for HSCT have been very positive 05:12 “In a randomised trial, [HSCT] was just hands down much better than any [other] drug. All the drugs you use for MS are based on approval for slowing disease activity. That is slowing the number of relapses or slowing the rate of progression of disability but not stopping it or not reversing it. Often you stay on these drugs indefinitely. A transplant, on the other hand, is a one-time treatment and afterwards, you get better, your neurologic disability reverses, nothing else had done that.” It's important to consider the disease trajectory, risks, and benefits of stem cell transplants. 14:02 “MS causes accelerated loss of brain volume, that is brain atrophy. Unfortunately, as we age, we get brain atrophy and a normal, very low, but normal decline. But once you get MS, that decline takes a much sharper drop, and you're losing neural function a lot faster than normal ageing. For some reason, that's not viewed as a sub-acute or semi-emergency situation that you want to reverse. Traditional drugs have mostly just slowed that rate of decline, but it's still faster than what happens with normal ageing. I would think a more aggressive approach up front would be wise, but you always have to remember [the] risk–benefit. If we could do a stem cell transplant with zero risk of mortality, I would say absolutely for everybody. But you can't do that right now.” A medical speciality and institute for autoimmunology could help push the field forward 34:20 “There are 80 different autoimmune diseases that I can think of offhand. They're all “homeless” in different departments like Crohn's disease [which is] in gastroenterology, Scleroderma [which] is in rheumatology, and multiple sclerosis [which] is in neurology. They're all separated [into] different areas. If there was a better organisation, beginning at a federal level with a national institute of autoimmune diseases that supports centres of excellence around the country, that would really help this go forward.” Want to learn more about living a full and happy life with multiple sclerosis? Sign up to our newsletter to hear our latest tips. More info and links: Visit Professor Burt's website Read Professor Burt's new book on HSCT for autoimmune diseases ‘Everyday Miracles' Check out Professor Burt's medical textbook ‘Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases' Find out more about the StarMS trial in the UK New to Overcoming MS? Visit our introductory page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS. Professor Richard Burt's bio: Professor Richard Burt is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University, and CEO of Genani Biotechnology. He endeavored for 35 years, first with animal models and then with some of the world's first clinical trials, to bring the field of stem cell and cellular therapy to the patients' bedsides. Publishing Professor Burt has published more than 145 first-author articles and is the editor of four medical textbooks. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institutes of Health (NIH) $10 million multicenter contract to develop stem cell clinical trials for autoimmune diseases. Hematopoietic stem cell transplants Professor Burt performed America's first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn's disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP) and published the world's first randomised clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. Awards and achievements He has been awarded the Leukemia Scholar of America, the Lupus Foundation of America Fidelitas Award, the van Bekkum Award by the European Society for Blood and Marrow Transplantation, the Distinguished Clinical Achievement Award by the Clinical Research Forum, and the European Group for Blood and Marrow Transplantation Clinical Achievement Award. Professor Burt was presented in Vatican City, Rome, with the “Keys to the Vatican,” was a speaker at the Festival of Thinkers in Leadership in Healthcare in the United Arab Emirates and chaired the biotechnology session at the Baku Azerbaijan International Humanitarian Forum. Professor Burt was recognised by Science Illustrated for accomplishing one of the top 10 medical breakthroughs for the next 10 years and by Scientific American as one of the top 50 individuals for improving humanity and outstanding leadership.
In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: 1. “How I Treat Peripheral T-cell Lymphoma?”:https://pubmed.ncbi.nlm.nih.gov/24615779/2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas:https://pubmed.ncbi.nlm.nih.gov/34921960/3. Ro-CHOP Phase III study (LYSA): Romidepsin-CHOP vs CHOP in peripheral T-cell lymphoma:https://pubmed.ncbi.nlm.nih.gov/34843406/4. RCT of autologous vs allogeneic HSCT as part of 1st line therapy in poor risk peripheral T-cell lymphoma:https://pubmed.ncbi.nlm.nih.gov/33512419/5. A phase 2 biomarker-driven study of ruxolitinib in T-cell lymphomas:https://pubmed.ncbi.nlm.nih.gov/34653242/6. JACKPOT8 study: Selective JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma:https://ash.confex.com/ash/2020/webprogram/Paper134650.html
Dr. Maria Bettinotti stresses the importance of HLA consultation for optimal clinical service to bone marrow and hematopoietic stem cell transplant programs. Join us to learn more about “best practices” in BMT/HSCT HLA testing and clinical consultation.
In this week's episode, we'll review a detailed safety profile of acalabrutinib versus ibrutinib in patients with previously treated chronic lymphocytic leukemia, discuss a report that leukocyte inflammation contributes to trauma-induced coagulopathy by oxidation and degradation of fibrinogen, and finally, discuss a pharmacokinetic-pharmacodynamic analysis that shows higher abatacept exposure decreases occurrence of acute graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) from an unrelated donor.
What can Milan Kundera teach us about leadership and sensemaking? That's the central question in this episode of the Sense and Signal podcast. Jodah and Dan welcome frequent guests Jesan Sorrells and Zoe Fragou to explore what Kundera – and other novelists – can teach leaders. Topics include leadership lessons from Milan Kundera's novels, historical amnesia in political leadership and workplace leadership, and the difference between ideology and Imagology and its impact on our sensemaking. And Zoe Fragou shares a story about being canceled by Greek nationalists on TikTok. A valuable podcast for those interested in political and workplace leadership and literature. MORE ABOUT ZOE FRAGOU Zoe' Fragou's LinkedIn: https://www.linkedin.com/in/fragouzoe/ Zoe Fragou's blog post “Positive Psychology v. Toxic Positivity” blog post - https://cto.academy/positive-psychology-vs-toxic-positivity/ MORE ABOUT JODA JENSEN https://www.linkedin.com/in/jodah/ MORE ABOUT DAN TARKER https://www.linkedin.com/in/dantarker/ https://www.danieltarker.com ABOUT JESAN SORRELLS Jesan Sorrells is the CEO and Founder of HSCT Publishing, LLC. HSCT is remote-first, video-based, software publishing platform company located in the Dallas-Fort Worth Metroplex. HSCT seeks to help organizations manage and reduce the impact of workplace conflict, encourage organizational innovation, and increase optimal outcomes around leadership development, conflict management and change management. HSCT leverages content platforms, training, and education via their Leadership Toolbox and LeadingKeys products. Jesan's latest book 12 Rules for Leaders: The Foundation of Intentional Leadership (2022) advances the idea that all problems in all organizations can be solved through the intentional application of effective leadership practices and principles. Leaders who have heard Jesan's message have changed cultures, changed organizations, and changed their work lives by changing their mindsets, their teams, and their organizations. Jesan hosts and produces the Leadership Lessons from the Great Books podcast, and previously published Marketing for Peace Builders: How to Market Your Value to a World in Conflict, in 2016 and My Boss Doesn't Care: 100 Essays Disrupting Your Workplace by Disrupting Your Boss, in April 2019. --- Send in a voice message: https://podcasters.spotify.com/pod/show/daniel-tarker/message
The Root Cause Medicine Podcast is created by Rupa Health, the best way to order, track & manage results from 30+ lab companies in one place for free. The Root Cause Medicine Podcast is a weekly one-on-one conversation with renowned medical experts, specialists, and pioneers who are influencing the way we look at our health and wellbeing. This week we're joined by Dr. Richard Burt, Chief of the Division of Immunotherapy, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. In this episode, Dr. Richard Burt shares his insights on hematopoietic stem cell transplant (HSCT) for autoimmune disorders. For thirty-five years, Dr. Burt dedicated himself to advancing stem cell and cellular therapy, beginning with animal models and, later, some of the world's first clinical trials. He authored over 145 articles, mostly as the first author, and edited four medical textbooks. As the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR), he led the way in developing stem cell clinical trials for autoimmune diseases, securing a National Institute of Health (NIH) $10,000,000 multi-center contract. Dr. Burt performed America's first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn's disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP). He also published the world's first randomized clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. Dr. Burt's pioneering stem cell work earned him recognition as one of the top 50 people in the world for improving humanity by Scientific American in 2006, along with A1 Gore and Steve Jobs. In 2011, Science Illustrated recognized his stem cell work as one of the top 10 advances of the decade. Key Takeaways: What is a hematopoietic stem cell transplant? Hematopoietic stem cell transplantation (HSCT) is a medical procedure where multipotent stem cells are transplanted into a patient, typically from bone marrow, peripheral blood, or umbilical cord blood. These cells can replicate and produce new, healthy blood cells, which can rejuvenate or repair damaged tissue in different organs, and also help fight viruses and foreign tissue. While leukemia is caused by defects in the blood stem cells themselves, autoimmune diseases arise from defects in the immune cells produced by these stem cells. To treat autoimmune diseases, specialists target the effector cells responsible for the disease and eliminate them, then quickly regenerate healthy cells from the blood stem cell. By using HSCT to replace damaged or defective cells with healthy ones, physicians hope to mitigate the symptoms of autoimmune disorders and promote long-term recovery. This innovative approach to treatment is still undergoing testing and refinement, but it shows great promise in the fight against these debilitating diseases. Finding the optimal transplant regimen for autoimmune diseases If your regimen is too strong, whether it's myeloablative or non-myeloablative, you can have more toxicity and problems. If it's too weak, it's not going to be effective. And so you've got to find that right regimen. When finding the optimal transplant regimen for autoimmune diseases, the aim is to develop a treatment plan that maximizes the benefits of the transplant while minimizing the risks and complications associated with it. An optimal transplant regimen for autoimmune diseases involves selecting the appropriate donor, considering the type of transplant, choosing the right conditioning regimen, and determining the timing and dosing of immunosuppressive medications. Financial toxicity in American healthcare systems Financial toxicity is a growing concern in America, particularly in medical treatments. Unfortunately, this often leads to patients being prescribed expensive treatments that may not be the best option for their specific needs. To achieve successful outcomes with hematopoietic stem cell transplantation, two key factors need to be considered: patient selection and the conditioning regimen used. However, due to the financial pressures facing healthcare providers and institutions, specialists may feel obligated to prescribe expensive treatments, even if they are not necessarily the most appropriate option for the patient. This can be a major source of frustration for patients, who may struggle to afford these treatments or may not receive the care that they truly need. Dr. Burt emphasizes the importance of physicians taking responsibility for their patient's care and being mindful of the financial implications of their recommendations. Rather than being driven solely by financial considerations, doctors should focus on providing the best possible care for their patients. By doing so, they can help to mitigate the effects of financial toxicity and ensure that patients receive the treatments that are best suited to their individual needs.
Welcome back to our 3rd and initially unplanned episode with Dr. Richard Burt, author of the recently released book, Everyday Miracles and the OG provider of HSCT here in the US. Let me explain why we thought it would be useful for our listeners, as well as Dr. Burt to come back and re-hash some of Dr. Burt's touch points from the first two episodes. In particular his stance on NOT treating PPMS and non-active SPMS with HSCT. You see, after the first two episodes, I witnessed rumblings of concern and discontent within the online HSCT community. I belong to multiple HSCT groups and most had at least one or two conversations going on addressing Dr. Burt's most recent interviews, including ours on this podcast. So, who was most concerned? Well, primarily PPMS patients, and non-active SPMS patients who are either considering HSCT, are already booked to have HSCT or those who've recently had HSCT. I 100% understand how Dr. Burt's stance on the efficacy of HSCT on their types of MS would have been reason for pause. Knowing that, I felt a responsibility to revisit the topic with him and drill down on the details. It would also give us a chance to ask him a couple of questions we missed on the first interview, like dietary restrictions before and after HSCT as well as questions on second transplants. We feel so fortunate that Dr. Burt graciously agreed to come on again an address a lot of these pressing issues. Also, if you hold on until the end, Jodi and I have a short chat about what we took away from today's interview and recap our thoughts on our entire experience with Dr. Burt. Because she and I have had HSCT, and each in different facilities, Russia and Mexico, we have a unique perspective and are able to relate to the concerns of an HSCT patient no matter what stage they're at in their HSCT journey. EPISODE NOTES: - 2nd transplants - Were you misdiagnosed? - Do you even have MS? - Many diseases mimic MS - The average percentage of patients who relapse post HSCT - Explaining in detail his thoughts on treating PPMS and non-active SPMS patients - What is RPMS (relapsing progressive MS) and would he offer HSCT to RPMS patients? - The type of regimen he would recommend If progressive MS is treated with HSCT - If not HSCT, what types of treatments does he recommend for PPMS and non-active SPMS patients? - Does he have any dietary recommendations for HSCT patients either before or after HSCT? - His thoughts on carbohydrates - The Epstein Barr virus (EBV) connection to MS - Following EBV titers after transplant LINKS: Episode #1 on YouTube: https://youtu.be/ezjhqHtYA8Y This episode, #2 of 2, on YouTube: https://youtu.be/40dqLdIeZlc Dr. Burt's book, EVERYDAY MIRACLES: https://www.amazon.com/Everyday-Miracles-Scleroderma-Autoimmune-Hematopoietic/dp/1637631251 Dr. Burt's website: https://astemcelljourney.com/about/drrichardburt/ Email to apply for HSCT with Dr. Burt: BURTRRMSTrial@scrippshealth.org THE MS GYM: Website YouTube Facebook Instagram BROOKE SLICK: Website Instagram JODI FELTHAM: TikTok Instagram
Warrior: Matt LeFrance AI: Multiple Sclerosis HSCT: June-July 2022 Superpower: peace of mind How do you know what to expect? From whom do you seek feedback? How do you decide to take the next step? Diagnosed just after college at the young age of 25 when he experienced double vision and a variety of doctors had a hard time understanding what was going on, Matt was diagnosed after a MRI revealed a lesion on his brain stem. As he pondered what was next, despite feeling as though life was ending when it should be only just beginning, Matt spent time researching his options for treatment before aging out of insurance coverage. Tune in to learn more about Matt's research efforts, his natural approach to managing MS for thirteen years before HSCT, and how he fared during his time in Puebla at Clinica Ruiz. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore the world map. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and engineer the audio to make this podcast possible. You can find us both when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician. Resources: Best Bet Diet and MS Hope
Dr Richard K. Burt, a world leading pioneer who performed America's first hematopoietic stem cell transplant (HSCT) to treat multiple sclerosis, discusses how he developed this innovative procedure and its future in the treatment of MS. While the treatment is only suitable for certain MS patients it can be life changing. The US's National MS Society says there is growing evidence that HSCT may be highly effective for people with relapsing remitting MS who meet very specific characteristics. The society adds it can greatly reduce and potentially even end MS disease activity in some. But the treatment is not without its risks and patients have died. However, as Richard argues in this podcast and his recently published book: Everyday Miracles Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant not all types of stem cell transplantation are the same and that it's vital that both doctors and patients understand the different approaches. That's because the type of stem cell technique used can affect the risks and effectiveness of the treatment for both MS and other forms of auto-immune disease. And an effective treatment for MS is desperately needed. Currently researchers are also looking at the use of high level vitamin D in the treatment of the disease. While current drugs known as disease modifying therapies may slow the progress of the disease, they cannot stop it. Dr Richard K. Burt is a Fulbright Scholar, Professor of Medicine at Scripps, a tenured retired Professor at North Western and CEO of Genani Biotechnology. In addition to performing America's first hematopoietic stem cell transplant for MS, he also carried out the first procedures in the US for a number of other auto-immune disease too. He was recognised by Scientific American as one of the Top 50 individuals for improving humanity and outstanding leadership. His book: Everyday Miracles Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant is published by Forefront Books. The host of the podcast, Liz Tucker is an award winning medical journalist and former BBC producer and director. You can follow Liz on Twitter at https://twitter.com/lizctucker and read her Substack newsletter about the podcast at https://liztucker.substack.com If you would like to support this podcast you can do so at patreon.com/whatyourgpdoesnttellyou or via PayPal at https://www.patreon.com/WhatYourGPDoesntTellYou What Your GP Doesn't Tell You has been selected by Feedspot as one of the top 20 UK Medical Podcasts https://blog.feedspot.com/uk_medical_podcasts/
In this episode, we dive into the considerations behind choosing HLA-matched vs. haplo-identical HSCT donors and the clinical innovations that are driving increases in haplo-identical HSCT.
Welcome to part two of two of our interview with Dr. Richard Burt. I can't tell you how many people have reached out to me after listening to part one and how anxious they are to see what awaits in part two. I even had one listener message me to say the interview with Dr, Burt should be required watching for everyone with MS, and I'm not going to disagree with that deduction. If you have PPMS, whether you're considering HSCT or not, you should definitely listen to this episode. Dr. Burt completely reframes the type of disease PPMS is or isn't. If you want to hear about the future of organ and tissue repair including but not exclusive to remyelination, you should listen to this episode. Those topics are just scratching the surface of what this medical innovator brings to the table for the future of the treatment of chronic illnesses, debilitating injuries, and to the exciting new world of neuroregeneration. I feel certain that what he's working on today is laying the groundwork for treatments that will be considered commonplace over the next 30 years. Before we jump into this next episode, I wanted to let you know that this episode will be available to view on the MS Gym's YouTube page, and there will be links in the episode notes to that YouTube page. There will also be links to part one of this interview as well as links to Dr. Burt's book, and his website, as well as an email, where you can contact Dr. Burt's team if you're considering HSCT. EPISODE NOTES: - His thoughts on PPMS and why he doesn't treat it - How disease labels can evolve over time - How HSCT drug protocols vary per autoimmune disease - What can trigger a relapse post HSCT - IPS stem cells and neuroregeneration - Starting a new biotech company - The future of HSCT in Chicago - How IPS could help patients with SPMS and PPMS - Where patients can receive non-myeloablative HSCT in the US now - Neurodegenerative treatment for non-active SPMS and PPMS - Pseudo flares post HSCT and what can cause them…don't panic! - Tweaking the healthcare system to make the patient first - Medicine is a profession, healthcare is a business LINKS: Episode #1 on YouTube: https://youtu.be/ezjhqHtYA8Y This episode, #2 of 2, on YouTube: https://youtu.be/40dqLdIeZlc Dr. Burt's book, EVERYDAY MIRACLES: https://www.amazon.com/Everyday-Miracles-Scleroderma-Autoimmune-Hematopoietic/dp/1637631251 Dr. Burt's website: https://astemcelljourney.com/about/drrichardburt/ Email to apply for HSCT with Dr. Burt: BURTRRMSTrial@scrippshealth.org THE MS GYM: Website YouTube Facebook Instagram BROOKE SLICK: Instagram
Warrior: Mike AI: Multiple Sclerosis HSCT: January 17, 2022 Superpower: acceptance and grace Where does kindness hit you? To what extent do you seek grace? How well do you find acceptance? We first met Mike in Season 7, shortly after he found out about HSCT. After battling with insurance and seeking HSCT at different clinics in the United States, Mike considered a variety of factors in his decision to pursue treatment in Monterrey, Mexico. As Mike works to support physical improvements despite spasticity post-transplant and a battle with COVID, he is finding room for his superpowers of acceptance and grace. Tune in to learn more about the ‘hiccups' that Mike encountered and their resolution, as well as considerations for family and recovery. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore the world map. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and engineer the audio to make this podcast possible. You can find us both when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician.
I'm super excited about these next two episodes! Of course, any episode that has to do with HSCT (hematopoietic stem cell transplant) is super important to me. For the last 10 years, I've been a vocal advocate for HSCT. Screaming about it from the top of my lungs through social media, blogging, and to anyone who would listen or inquired. As you may or may not know, my co-host, Jodi, and I have both received HSCT for our MS. I had mine in Russia 10 years ago, and Jodi in Mexico in 2018. So when Dr. Richard Burt's team reached out to us to discuss all things HSCT, as well as his recently released book, Everyday Miracles, that puts forth, in lay terms, his long road to accomplishing his goals, we were beyond open to having the opportunity to ask all the questions we ever wanted to know. Those questions include the reasoning behind his choices for inclusion and exclusion of certain patients for this treatment...in particular, MS patients. Questions like…Which MS patients does this treatment work for? Who doesn't it work for? and why? So who is Dr Richard Burt? He's the determined and innovative physician who pioneered the use of HSCT in the US. Within the HSCT community, he's considered the Godfather of HSCT, and yes, in case you're wondering, he IS the Dr. who treated actress Selma Blair. For the last 35 years, with laser focus and blinders on to block out any peripheral static from naysayers, Dr. Burt has been quietly and methodically raging against the machine that is today's medical system. Armed with the knowledge he gained while treating patients with leukemia with HSCT, he felt certain it could potentially halt the progression of certain autoimmune diseases and in many cases, reverse symptoms. So he plowed forward with a mission to prove his hypothesis. But it wouldn't happen overnight. There were randomized trials, hundreds of patients, many diseases and, in the end, life-changing success stories. Dr. Burt was the first doctor in the US to give hope to patients with MS, Lupus, Crohn's, Stiff Person Syndrome and CIDP, when in the past they'd grappled with a life filled with a long list of ineffective drugs and certain disease progression. To be clear, just because he was butting up against systemic red tape here in the US, doesn't mean he wasn't becoming a highly decorated peer by the international medical community and beyond. His list of awards granted by esteemed medical organizations is lengthy and impressive. I mean seriously, how many doctors do you know who've been presented with the "keys to the Vatican" in Vatican City, Rome? He was even recognized by Science illustrated for accomplishing one of the top 10 medical breakthroughs for the next 10 years. And, the forward for his book was written by the Dalai Lama! Yes! Dr. Burt has got the juice! So much so that we had to squeeze it out in two full episodes. Both of which are packed with answers from pointed questions that you won't find anywhere else. Asked by HSCT veterans who, for over a decade, have been privy to all the insider speculation regarding Dr. Burt's methodology. Like why he will or won't treat certain MS patients, why he uses certain drugs in his protocol, and what he considers a successful HSCT. It's time to dig in and peel back the curtain on HSCT with Dr. Richard Burt. EPISODE NOTES: - Dr. Burt's book, Everyday Miracles - Making HSCT easy to understand - 54 patient stories - Being a patient-oriented physician - Insurance coverage - How HSCT works - The mistake of thinking that the stem cells are what resets your immune system - Whose stem cells are used? - Myeloablative or non-myeloablative HSCT…which one does Dr. Burt prefer for AI disease - HSCT for cancer vs. an autoimmune disease - Stronger protocols don't always mean better - A one-time treatment - How long will it last? - The important role of measuring brain atrophy in MS progression - The colonialistic attitude of doctors toward patients - The risks associated with a myeloablative protocol - What is the definition of a successful HSCT - The difference between active and non-active SPMS - Neurodegeneration…it's tricky - Ocrevus, neurodegeneration and progression to SPMS - Your immune system is your ally - MS drugs are toxins - Why he used ATG as part of his HSCT protocol LINKS: This episode on YouTube: https://youtu.be/ezjhqHtYA8Y Dr. Burt's book, EVERYDAY MIRACLES: https://www.amazon.com/Everyday-Miracles-Scleroderma-Autoimmune-Hematopoietic/dp/1637631251 Dr. Burt's website: https://astemcelljourney.com/about/drrichardburt/ Email to apply for HSCT with Dr. Burt: BURTRRMSTrial@scrippshealth.org THE MS GYM: Website YouTube Facebook Instagram BROOKE SLICK: Instagram
Warrior: Ali Strong AI: Multiple Sclerosis HSCT: November, 2017 Superpower: Acceptance What do you do for yourself that brings you joy? Are you someone who accepts moderation? To what extent do you find balance in life? Check in with Ali Strong to recount her experience finding her way to and through HSCT and learn how she is feeling now at more than five years post-transplant, including her struggles with menopause, disordered eating, and mental health. Join Ali and Zen Jen in discussion about Dr. Burt's latest book and what's to come with the podcast. Be sure to visit our website, HSCTWarriorsPodcast.org where you can find notes from today's episode, submit ideas or feedback, or connect with HSCT Warriors, Inc. and schedule time to “Talk with a Warrior”, find the latest research and resources, or explore the world map. Special thanks to musical genius Billy Alletzhauser for sharing his superpowers to produce the soundtrack, and engineer the audio to make this podcast possible. You can find us both when you subscribe on SoundCloud, iTunes or wherever you find podcasts. It has been great to connect with Warriors worldwide, so please reach out if you're interested in sharing your story. We would love to learn how the podcast has helped your journey with autoimmune disease so if you could take a moment, leave us a comment on instagram or share feedback on our website. We hope you'll tune in next Wednesday for another episode, highlighting another HSCT Warrior. Until then, be a snowflake and embrace your superpowers. Be kind. Be well. _________________________________ Jen Stansbury Koenig and the producers disclaim medical influence and responsibility for any possible adverse effects from the use of information contained herein. If you think you have a medical problem, please contact a licensed physician.
Today, we're talking about a topic that you've told me is the topic that you'd most like me to cover on this podcast -- autologous hematopoietic stem cell transplantation, or HSCT. And I'm dedicating this entire episode of RealTalk MS to a deep dive on the subject with the man who pioneered autologous HSCT as a treatment for relapsing-remitting MS, Dr. Richard Burt. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Autologous HSCT with Dr. Richard Burt :23 Dr. Richard Burt takes us on a deep dive into autologous HSCT for MS :57 Share this episode 54:38 Have you downloaded the free RealTalk MS app? 54:59 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/281 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Amazon: Everyday Miracles: Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant by Dr. Richard Burt https://www.amazon.com/Everyday-Miracles-Scleroderma-Autoimmune-Hematopoietic/dp/B0BRNTJZ9X/ref=sr_1_1 National MS Society: aHSCT in MS https://nationalmssociety.org/Treating-MS/aHSCT Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 281 Guest: Dr. Richard Burt Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy
© 2020-2025 Ivy Podcast Discovery LLC
